Last reviewed · How we verify
Reactive Corticosteroid Taper Regimen
At a glance
| Generic name | Reactive Corticosteroid Taper Regimen |
|---|---|
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Cushingoid
- Photophobia
- Vomiting
- Fatigue
- Gait Disturbance
- Pyrexia
- Hepatic Enzyme Increased
- Headache
- Somnolence
- Claustrophobia
- Phonophobia
- Cough
Key clinical trials
- Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency (PHASE1, PHASE2)
- Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: